Pharmacokinetics

Author Title Reference Year View
Davidsson, P et al. Studies of Nontarget‐Mediated Distribution of Human Full‐Length IgG1 Antibody and Its FAb Fragment in Cardiovascular and Metabolic‐Related Tissues Journal of Pharmaceutical Sciences, Vol. 104, Issue 2, DOI: 10.1002/jps.24368 2015 Read
Chakravarthy, K et al. Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis BMC Musculoskeletal Disorders 2014, 15:409 2014 Read
Giddabasappa, A et al Abstract 4293: Whole-body bio-distribution of anti-5T4-mcMMAF (anti-5T4-ADC) using fluorescence molecular tomography (FMT) imaging in a non-small cell lung cancer mice model Cancer Res October 1, 74; 4293 2014 Read
Burns, D et al Improving Efficiency and Data Reproducibility through the Use of Fully Integrated Automation in Bioanalysis of Biotherapeutics AAPS 2014 Poster
Kozhich, A et al Multiparameter Comparison of PK Immunoassay for a Therapeutic Monoclonal Antibody Implemented on Four Different Platforms AAPS 2014 Poster
Collet, J et al Evaluating Multiple Technology Platforms to Meet Challenges of Developing a Ligand Binding Assay to Support Clinical Trials Conducted in Adult or Pediatric Populations AAPS 2014 Poster
Joyce, AP, et al One Mouse, One Pharmacokinetic Profile: Quantitative Whole Blood Serial Sampling for Biotherapeutics Pharm Res. 2014 Jan 24 2014 PMID
Henderson, SJ et al Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β Brain (2013) doi: 10.1093/brain/awt308 2013 Read
Hall, CM et al An extended range generic immunoassay for total human therapeutic antibodies in preclinical pharmacokinetic studies J Immunol Methods. 2013 Jul 31;393(1-2):70-3 2013 PMID
Piper, E et al A phase II placebo controlled study of tralokinumab in moderate-to-severe asthma Eur. Respir. J., Feb 2013; 41: 330 - 338 2013 Read
Liu, R et al Rapid development of multiple 'fit-for-purpose' assays on an automatic microfluidic system using a streamlined process in support of early biotherapeutics discovery programs Bioanalysis 2013 Jul;5(14):1751-63 2013 Read
Patel, V et al Automating bioanalytical sample analysis through enhanced system integration Bioanalysis 2013 Jul;5(13):1649-59 2013 PMID
Jonsson, O et al Capillary microsampling and analysis of 4-μl blood, plasma and serum samples to determine human a-synuclein elimination rate in mice Bioanalysis 2013, 5(5) 449-462 2013 Read
Liu, XF et al Validation of a Gyrolab™ assay for quantification of rituximab in human serum J Pharmacol Toxicol Methods, 2012, 65(3), 107-114 2012 PMID
Shih, J et al Implementation of a universal analytical method in early-stage development of human antibody therapeutics: application to pharmacokinetic assessment for candidate selection Bioanalysis 2012, 4(19) 2357-2365 2012 Read
Wang, W et al Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies Mol Immunol 2011, 48 860-866, doi:10.1016/j.molimm.2010.12.009 2011 PMID
Ni, YG et al A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo J Lipid Res 2011, 52(1) 78-86. 2011 PMID
van der Woude, C et al Phase I, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of NI-0401 (a Fully Human Anti-CD3 Monoclonal Antibody) in Patients with Moderate to Severe Active Crohns Disease Inflamm Bowel Dis. 2010, 16(10) 1708-16 2010 PMID
Mora, J et al Application of the Gyrolabª platform to ligand-binding assays: a user's perspective Bioanalysis 2010, 2 (10) 1711-1715 2010 PMID
Singh, D et al A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma BMC Pulm Med. 2010, 8 10:3. 2010 PMID
Oh, C K et al An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males Brit J Pharmacol 2010, 69 (6) 645-655 2010 PMID
Roman, J et al Application of miniaturized immunoassays to discovery pharmacokinetic bioanalysis J Pharmacological Toxicological Methods, online December 2010 2010 PDF
Mallozzi, C & Kavosi, M Gyrolab Demonstrated Shorter Assay Time and Broader Dynamic Range Compared to a Plate Based ELISA with a Generic Human IgG Assay in Rat Serum Inaugural North American Gyrolab Seminar 2010 PDF
Colombo, L et al New analytical technologies: Pharmaceutical applications to proteins and antibodies. An industry perspective National meeting on medicinal chemistry (NMMC), Abano Terme, Italy, Book of abstracts, p39-40, October 2010 2010
Salimi-Moosavi, H High Throughput Ligand Binding Assay for Therapeutic Antibodies and Biomarkers Using Gyros Microfluidic Instrument NBC Symposium: Advantages of Non-Traditional Technologies for Ligand Binding Assay Development, 2010 2010 PDF
Hannam, S et al Minimising Volume, Maximising Returns European Pharmaceutical Review, Discovery Technology, Spring 2010 2010 Read
Shen, H-W & Yu, A-M New analytical technologies for biological discovery Bioanalysis 2010, 2(2), 181-184 2010 Read
Inganas, M Application report 207: Miniaturizing immunoassays
for improved performance
Gyros Application Report Product Information
Crosasso, C et al Gyrolab in a GxP environment: the Merck Serono experience PDF

You can view further information on selected references through the link in the column ‘View’ on the far right.

PMID: PubMed ID
PDF: Download the document as a PDF file